BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the more accurate screening, diagnosis and treatment of breast cancers, announced its sponsored placement in a MarketScreener.com editorial titled From Healthcare to Automation: Investing In Next AI Wave. The article discusses the growing adoption of specialized AI applications across industries and features Izotropic’s IzoView technology as a rare early-stage medtech opportunity with the potential to establish a new standard of care in breast cancer imaging.

To view the full press release, visit https://ibn.fm/OOA6A

About Izotropic:

More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…

37 minutes ago

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (“ADC”) program beyond the…

20 hours ago

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Adds California Hub to Growing Pharmacy Network

Earth Science Tech (OTC: ETST) recently continued its expansion in the healthcare, pharmacy and telemedicine…

21 hours ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725…

1 day ago

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing…

6 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…

6 days ago